Tags

Type your tag names separated by a space and hit enter

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Climacteric. 2005 Sep; 8(3):251-62.C

Abstract

OBJECTIVES

To assess the efficacy and tolerability of risedronate, a pyridinyl bisphosphonate, in preventing loss of bone mineral density (BMD) of the lumbar spine and proximal femur in early postmenopausal women.

METHODS

A total of 383 patients were randomly assigned to receive risedronate 2.5 or 5 mg or placebo once daily for 24 months. All patients received 1 g elemental calcium daily. BMD was measured by dual X-ray absorptiometry at baseline and at 3, 6, 12, 18, and 24 months.

RESULTS

Risedronate 5 mg significantly increased BMD at the lumbar spine and femoral neck and trochanter in early postmenopausal women. Significant results were observed as early as 3 months. In the control calcium-supplemented group, BMD decreased steadily at each site throughout the study. The mean percentage change from baseline in BMD in the risedronate 5 mg group was significantly different from that in the control group at each determination at each site. At 24 months, the differences were 4.5 +/- 0.45% at the lumbar spine, 3.3 +/- 0.49% at the femoral neck, and 4.3 +/- 0.67% at the femoral trochanter. Risedronate 2.5 mg maintained BMD at each site, although the effect was less pronounced than that of risedronate 5 mg. Risedronate was well tolerated and was not associated with an increased incidence of overall or upper gastrointestinal adverse events.

CONCLUSIONS

Risedronate 5 mg prevents bone loss in early postmenopausal women, is well tolerated, and represents an effective choice to maintain bone mass and prevent osteoporosis.

Authors+Show Affiliations

The University of Sydney, Endocrinology and Metabolism, C64, Level 6, Concord Hospital Medical Centre, Concord Repatriation General Hospital, Concord, New South Wales 2139, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16390757

Citation

Hooper, M J., et al. "Risedronate Prevents Bone Loss in Early Postmenopausal Women: a Prospective Randomized, Placebo-controlled Trial." Climacteric : the Journal of the International Menopause Society, vol. 8, no. 3, 2005, pp. 251-62.
Hooper MJ, Ebeling PR, Roberts AP, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005;8(3):251-62.
Hooper, M. J., Ebeling, P. R., Roberts, A. P., Graham, J. J., Nicholson, G. C., D'Emden, M., Ernst, T. F., & Wenderoth, D. (2005). Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric : the Journal of the International Menopause Society, 8(3), 251-62.
Hooper MJ, et al. Risedronate Prevents Bone Loss in Early Postmenopausal Women: a Prospective Randomized, Placebo-controlled Trial. Climacteric. 2005;8(3):251-62. PubMed PMID: 16390757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. AU - Hooper,M J, AU - Ebeling,P R, AU - Roberts,A P, AU - Graham,J J, AU - Nicholson,G C, AU - D'Emden,M, AU - Ernst,T F, AU - Wenderoth,D, PY - 2006/1/5/pubmed PY - 2006/3/1/medline PY - 2006/1/5/entrez SP - 251 EP - 62 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 8 IS - 3 N2 - OBJECTIVES: To assess the efficacy and tolerability of risedronate, a pyridinyl bisphosphonate, in preventing loss of bone mineral density (BMD) of the lumbar spine and proximal femur in early postmenopausal women. METHODS: A total of 383 patients were randomly assigned to receive risedronate 2.5 or 5 mg or placebo once daily for 24 months. All patients received 1 g elemental calcium daily. BMD was measured by dual X-ray absorptiometry at baseline and at 3, 6, 12, 18, and 24 months. RESULTS: Risedronate 5 mg significantly increased BMD at the lumbar spine and femoral neck and trochanter in early postmenopausal women. Significant results were observed as early as 3 months. In the control calcium-supplemented group, BMD decreased steadily at each site throughout the study. The mean percentage change from baseline in BMD in the risedronate 5 mg group was significantly different from that in the control group at each determination at each site. At 24 months, the differences were 4.5 +/- 0.45% at the lumbar spine, 3.3 +/- 0.49% at the femoral neck, and 4.3 +/- 0.67% at the femoral trochanter. Risedronate 2.5 mg maintained BMD at each site, although the effect was less pronounced than that of risedronate 5 mg. Risedronate was well tolerated and was not associated with an increased incidence of overall or upper gastrointestinal adverse events. CONCLUSIONS: Risedronate 5 mg prevents bone loss in early postmenopausal women, is well tolerated, and represents an effective choice to maintain bone mass and prevent osteoporosis. SN - 1369-7137 UR - https://www.unboundmedicine.com/medline/citation/16390757/Risedronate_prevents_bone_loss_in_early_postmenopausal_women:_a_prospective_randomized_placebo_controlled_trial_ L2 - https://www.tandfonline.com/doi/full/10.1080/13697130500118126 DB - PRIME DP - Unbound Medicine ER -